The PD-L1 Expression Among Triple-Negative Breast Cancer Patients in Universitas Sumatera Utara Teaching Hospital, Indonesia.

Background: The emerging role of precision medicine among in oncologic science is a potentially explorable area to solve long-standing implication of triple-negative breast cancer (TNBC)'s management, especially by identifying programmed cell death ligand-1 (PD-L1) in its population.

Objective: To describe the PD-L1's expression among TNBC populations in our Indonesia-based centers.

Methods: This descriptive study was conducted in the teaching hospitals of Universitas Sumatera Utara ranging from April 2019 to July 2020.

Role of Hormonal Receptor in Predicting Sentinel Lymph Node Metastasis in Early Breast Cancer.

Background: Sentinel lymph node biopsy is one of the minimally invasive techniques that can confirm the presence of metastasis of regional lymph nodes in cancer. Sentinel lymph node biopsy can be done with a lymph mapping technique using blue-dye, radiotracer, or a combination of both. In developing countries, sentinel lymph node biopsy is often done with a single agent, which is the blue dye.

Accuracy of Methylene Blue Test as Single Technique for Sentinel Lymph Node Biopsy in Early Stages Breast Cancer.

Aim: Sentinel Lymph Node Biopsy (SLNB) establishes as a gold standard for diagnostic lymph node involvement in early breast cancer. Most of the developed country does not have radiotracer and nuclear medicine facilities. Unless in Indonesia there is Methylene Blue as an alternative agent for SLNB.